Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity
- PMID: 22678897
- DOI: 10.1002/eji.201141774
Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity
Abstract
Efficient presentation of peptide-MHC class I (pMHC-I) complexes to immune T cells should benefit from a stable peptide-MHC-I interaction. However, it has been difficult to distinguish stability from other requirements for MHC-I binding, for example, affinity. We have recently established a high-throughput assay for pMHC-I stability. Here, we have generated a large database containing stability measurements of pMHC-I complexes, and re-examined a previously reported unbiased analysis of the relative contributions of antigen processing and presentation in defining cytotoxic T lymphocyte (CTL) immunogenicity [Assarsson et al., J. Immunol. 2007. 178: 7890-7901]. Using an affinity-balanced approach, we demonstrated that immunogenic peptides tend to be more stably bound to MHC-I molecules compared with nonimmunogenic peptides. We also developed a bioinformatics method to predict pMHC-I stability, which suggested that 30% of the nonimmunogenic binders hitherto classified as "holes in the T-cell repertoire" can be explained as being unstably bound to MHC-I. Finally, we suggest that nonoptimal anchor residues in position 2 of the peptide are particularly prone to cause unstable interactions with MHC-I. We conclude that the availability of accurate predictors of pMHC-I stability might be helpful in the elucidation of MHC-I restricted antigen presentation, and might be instrumental in future search strategies for MHC-I epitopes.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Similar articles
-
Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability.J Immunol. 1996 May 1;156(9):3308-14. J Immunol. 1996. PMID: 8617954
-
Natural variants of the immunodominant HLA A11-restricted CTL epitope of the EBV nuclear antigen-4 are nonimmunogenic due to intracellular dissociation from MHC class I:peptide complexes.J Immunol. 1997 Dec 1;159(11):5383-90. J Immunol. 1997. PMID: 9548478
-
Pan-Specific Prediction of Peptide-MHC Class I Complex Stability, a Correlate of T Cell Immunogenicity.J Immunol. 2016 Aug 15;197(4):1517-24. doi: 10.4049/jimmunol.1600582. Epub 2016 Jul 8. J Immunol. 2016. PMID: 27402703 Free PMC article.
-
Class I MHC-peptide interaction: structural and functional aspects.Behring Inst Mitt. 1994 Jul;(94):48-60. Behring Inst Mitt. 1994. PMID: 7998914 Review.
-
Structural Prediction of Peptide-MHC Binding Modes.Methods Mol Biol. 2022;2405:245-282. doi: 10.1007/978-1-0716-1855-4_13. Methods Mol Biol. 2022. PMID: 35298818 Review.
Cited by
-
Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells.J Immunol. 2012 Dec 15;189(12):5549-60. doi: 10.4049/jimmunol.1102221. Epub 2012 Nov 21. J Immunol. 2012. PMID: 23175697 Free PMC article.
-
High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions.Cancer Immunol Res. 2019 Jan;7(1):50-61. doi: 10.1158/2326-6066.CIR-18-0395. Epub 2018 Nov 13. Cancer Immunol Res. 2019. PMID: 30425106 Free PMC article.
-
Selector function of MHC I molecules is determined by protein plasticity.Sci Rep. 2015 Oct 20;5:14928. doi: 10.1038/srep14928. Sci Rep. 2015. PMID: 26482009 Free PMC article.
-
TAPBPR promotes antigen loading on MHC-I molecules using a peptide trap.Nat Commun. 2021 May 26;12(1):3174. doi: 10.1038/s41467-021-23225-6. Nat Commun. 2021. PMID: 34039964 Free PMC article.
-
Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success.Cancers (Basel). 2023 Dec 2;15(23):5694. doi: 10.3390/cancers15235694. Cancers (Basel). 2023. PMID: 38067396 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials